The Medical Outpatient Care Center (MVZ) of University Hospital Frankfurt is becoming the first clinical partner in Germany to routinely offer the Proclarix test. This has been announced in a joint press release from the MVZ and the Schlieren-based manufacturer Proteomedix. Proclarix is a new blood-based test for the diagnosis of prostate cancer. Proteomedix had only made the new test commercially available in Europe in February of this year.
Professor Peter Wild from University Hospital Frankfurt: “Proclarix is an innovative new decision support tool to improve classification in prostate cancer diagnostics in men with elevated PSA levels. We are excited to be the first clinical partner in Germany to offer this test.” The test supports doctors in patient management with advanced bioinformatics. It combines this with the ease-of-use and high acceptance for patients of a blood-based biomarker test.
Ralph Schiess, CSO and co-founder of Proteomedix, also commented: “The clinical benefit of the Proclarix test was validated as part of an international multi-center study in which the Urology Clinic at the Frankfurt University Hospital, Prof. Dr. med. Felix Chun was also involved.”
Proteomedix is a spin-off from the Swiss Federal Institute of Technology in Zurich (ETH) with headquarters in the Bio-Technopark Schlieren-Zurich.
Related news
Contact us
Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?
info@greaterzuricharea.com